GSK secures ex-Greater China rights to KRAS-EGFR therapy; $110M upfront
GSK won global licensing rights excluding Greater China to develop and commercialize a KRAS-EGFR antibody-targeted cancer therapy. Deal includes $110 million upfront plus up to $1.185 billion in milestones, with initial trials starting in H2 2026.
A global licensing deal grants GSK rights (excluding Greater China) to develop and commercialize a novel KRAS-EGFR antibody-targeted therapy for major cancers, with $110 million upfront and up to $1.185 billion in milestones.
Initial trials begin in H2 2026.Original document: HUTCHMED (China) Limit…